Info

OTCQB Podcast

OTC Markets Group podcast series on the OTCQB Market, where we interview the entrepreneurs behind the companies that trade on the venture market.
RSS Feed
OTCQB Podcast
2024
March
February
January


2023
December
November
October
September
August
July
June
May
April
March
February
January


2022
December
November
October
September
August
July
June
May
April
March
February
January


2021
December
November
October
September
August
July
June
May
April
March
February
January


2020
December
November
October
September
August
July
June
May
April
March
February
January


2019
November
October
September
August
July
June
May
April
March
February
January


2018
December
November
October
September
August
July
June
May
April
March
February


2017
December
November
October
September
August
July
June
May
April
March
January


Categories

All Episodes
Archives
Categories
Now displaying: March, 2018
Mar 27, 2018

Kane Biotech Inc. (OTCQB: KNBIF) is a Canadian-based technology company engaged in the development and commercialization of products that prevent and remove microbial biofilms.

Mar 21, 2018

Chilean Metals Inc. (OTCQB: CMETF), formerly International PBX Ventures Ltd., is an exploration-stage company. The Company is engaged in exploring copper and gold on its various properties located in Chile and Nova Scotia.

Mar 15, 2018

First Cobalt (OTCQB: FTSSF) is focused on building a diversified global portfolio of assets that are highly leveraged to the cobalt market. Our projects include interests proximal to several major copper-cobalt ("Cu-Co") operations in the Central African Copperbelt in the DR Congo - and In Canada, an interest in the former producing Keeley-Frontier mine, a high-grade silver-cobalt mine (produced over 3.3 million pounds of cobalt and 19.1 million ounces of silver 1908 - 1965).

Mar 5, 2018

Wize Pharma (OTCQB: WIZPD) is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including Dry Eye Syndrome. Wize Pharma has inlicensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of Dry Eye Syndrome, and other ophthalmological illnesses, including Sjorgen's Syndrome and Conjunctivochalasis.

1